Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

By P. Ridker, Brendan M. Everett, T. Thuren, Jean G Macfadyen, W. Chang, Christie M. Ballantyne, F. Fonseca, J. Nicolau, W. Koenig, S. Anker and 18 more. New England Journal of Medicine, 2017

7,832 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/4514d1cdcd182412f72d241cad900be216b80e73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Immunology

In Molecular Biology

Citations in the corpus

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention (2022, background): “and human biomarker and experimental work to clinical fruition.(355,366,378) Indeed, the recent evidence that interventions of anti-inflammation can forestall the complications of atherosclerosis scratches merely the surface of the potential as novel therapeutics.”
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, methodology): “This study was the first to highlight the positive correlation between high-sensitivity C-reactive protein and CV events, where lower achieved high-sensitivity C-reactive protein values were directly correlated with a lower risk of future CV events.(548) Nevertheless, the FDA declined to approve can”
Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction (2018, positive): “After tissue injury CCR2 + monocytes and macrophages can produce IL-1 β 5 , a pro-inflammatory cytokine that promotes cardiovascular disease 15 .”
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies (2021, background): “Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al.; CANTOS Trial Group (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease.”
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms (2017, background): “A recent large proof of concept trial of anti-inflammatory therapy in patients after myocardial infarction (A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable PostMyocardial Infarc”
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “69 Also other proinflammatory cytokines, such as TNF-α and IL-17, have the capability, at least in preclinical studies, to induce cardiac arrhythmias.”